Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Post-Market CorPath Registry on the CorPath 200 System in Percutaneous Coronary Interventions (PRECISION)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2016 by Corindus Inc.
Information provided by (Responsible Party):
Corindus Inc. Identifier:
First received: August 2, 2013
Last updated: December 15, 2016
Last verified: December 2016
To collect data on the routine patterns of use, safety and effectiveness, including the clinical and technical performance of the CorPath 200 System, in the delivery and manipulation of coronary guidewires and stent/balloon catheters during PCI procedures.

Condition Intervention
Coronary Artery Disease
Coronary Disease
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Procedure: CorPath-assisted Percutaneous Coronary Intervention

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Target Follow-Up Duration: 3 Days
Official Title: A Post-Market Registry for the Evaluation of the CorPath 200 System Effectiveness in Percutaneous Coronary Interventions

Further study details as provided by Corindus Inc.:

Primary Outcome Measures:
  • Clinical Success [ Time Frame: In-hospital (72 hours or discharge, whichever occurs first) ]
    Less than 30% residual stenosis post PCI in the lesion(s) treated with the CorPath system, without in-hospital major adverse coronary events (MACE).

Secondary Outcome Measures:
  • In-hospital Major Adverse Coronary Events (MACE) [ Time Frame: In-hospital (72 hours or discharge, whichever occurs first) ]
    The composite of death, myocardial infarction, and target vessel revascularization that occurs within 72 hours of the procedure or prior to hospital discharge, whichever occurs first, in a subject treated with the CorPath 200 System.

  • Adverse Events [ Time Frame: In-hospital (72 hours or discharge, whichever occurs first) ]
    All Serious Adverse Events (SAEs) and Unanticipated Adverse Device Effects (UADEs) from the start of the CorPath procedure until the end of the study will be summarized.

Other Outcome Measures:
  • Overall Procedure Time [ Time Frame: During procedure ]
    Defined as the time measured from the insertion of the hemostasis sheath until the removal of the guide catheter.

  • PCI Procedure Time [ Time Frame: During procedure ]
    Defined as the time measured from the insertion of the guide catheter until the removal of the guide catheter.

  • Fluoroscopy and/or X-Ray Time [ Time Frame: During procedure ]
    As recorded by an X-Ray System utilized during the procedure.

  • Patient Radiation Exposure [ Time Frame: During procedure ]
    DAP (dose-area-product) and cumulative dose as recorded during the procedure.

  • Contrast Fluid Volume [ Time Frame: During procedure ]
    No additional description

  • Number of Conversions to Manual [ Time Frame: During procedure ]
    The overall number of conversions from the robotic PCI to manual PCI will be captured to analyze the technical success of the device.

  • Measurement of Lesion and Stented Segment Length [ Time Frame: During procedure ]
    1. Visual estimate by clinical operator prior to delivery of PCI device(s).
    2. CorPath 200 System measurement of the segment planned for treatment and length of deployed stent.
    3. Quantitative Coronary Angiography (QCA) of stented segment length

Estimated Enrollment: 2000
Study Start Date: August 2013
Estimated Study Completion Date: August 2017
Estimated Primary Completion Date: August 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Study Cohort
Subjects treated with CorPath-assisted Percutaneous Coronary Intervention (PCI)
Procedure: CorPath-assisted Percutaneous Coronary Intervention
Robotic-assisted Percutaneous Coronary Intervention
Other Name: Robotic-assisted Percutaneous Coronary Intervention

Detailed Description:
This is a prospective, single-arm, open-label, multi-center patient registry of the CorPath 200 System to examine its performance during PCI procedure and patient outcomes through 72 hours post-procedure or hospital discharge, whichever occurs first.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with coronary artery disease and with the clinical indication for Percutaneous Coronary Intervention (PCI).

Inclusion Criteria:

  1. Age >18 years.
  2. Patients with coronary artery disease undergoing Percutaneous Coronary Intervention (PCI) with the CorPath 200 system.
  3. The subject or the legal representative has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion Criteria:

  1. Concurrent enrollment in another device or drug study protocol that specifically excludes concurrent enrollment or that prevents collection of data required in this registry (concurrent participation in another registry is not an automatic exclusion criterion for this study).
  2. Failure/inability/unwillingness to provide informed consent.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01917682

Contact: Chris Cain, RN (508) 653-3335 ext 202

United States, California
UC San Diego Medical Center Recruiting
San Diego, California, United States, 92103
Contact: Bahman Ghannadian   
Principal Investigator: Ehtisham Mahmud, MD         
United States, Colorado
Valley View Hospital Recruiting
Glenwood Springs, Colorado, United States, 81601
Contact: Kim Williams   
Principal Investigator: Frank A. Laws, MD         
United States, District of Columbia
Medstar Washington Hospital Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Helen Zeraye   
Principal Investigator: Itsik Ben-Dor, MD         
United States, Florida
Orlando Regional Medical Center Recruiting
Orlando, Florida, United States, 32806
Contact: Pamela Peisner    321-841-3706   
Principal Investigator: Vijaykumar Kasi, MD         
United States, Georgia
North Georgia Heart Foundation Recruiting
Gainesville, Georgia, United States, 30501
Contact: Donna Patrick, RN   
Principal Investigator: Mark Leimbach, MD         
United States, Massachusetts
St. Elizabeth's Medical Center Recruiting
Boston, Massachusetts, United States, 02135
Contact: Lindsay Pothier   
Principal Investigator: Joseph P. Carrozza, MD         
United States, Michigan
Spectrum Health System Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Stacie VanOosterhout, MEd    616-486-2031   
Principal Investigator: David Wohns, MD         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55906
Contact: Mary Thum, MS    507-255-9405   
Principal Investigator: Rajiv Gulati, MD         
United States, New York
Columbia University Medical Center/New York-Presbyterian Hospital Recruiting
New York, New York, United States, 10032
Contact: Andy Morales   
Principal Investigator: Jeffrey Moses, MD         
St. Joseph's Hospital Health Center Recruiting
Syracuse, New York, United States, 13203
Contact: Tamer Ghobrial   
Principal Investigator: Ronald Caputo, MD         
United States, North Carolina
Carolinas Medical Center - Northeast Completed
Concord, North Carolina, United States, 28203
United States, Ohio
University Hospitals Case Medical Center Recruiting
Cleveland, Ohio, United States, 44106
Contact: Hiram Bezerra, MD   
Principal Investigator: Hiram Bezerra, MD         
United States, South Dakota
Sanford Health Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Amy Wittrock   
Principal Investigator: Tomasz Stys, MD         
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Doug Spaulding, RN    434-982-1058      
Principal Investigator: Michael Ragosta, MD         
Virginia Commonwealth Univ. Medical Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Laura Cei   
Principal Investigator: Luis Guzman, MD         
Shaare Zedek Medical Center Recruiting
Jerusalem, Israel, 91031
Contact: Astrid Rojansky   
Principal Investigator: Giora Weisz, MD         
Sponsors and Collaborators
Corindus Inc.
Principal Investigator: Giora Weisz, MD Columbia University Medical Center/New York-Presbyterian Hospital
Study Director: Chris Cain VP, Clinical Affairs
  More Information

Additional Information:
Responsible Party: Corindus Inc. Identifier: NCT01917682     History of Changes
Other Study ID Numbers: PRECISION CorPath Registry
Study First Received: August 2, 2013
Last Updated: December 15, 2016
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Corindus Inc.:
robotic-assisted PCI
coronary intervention
CorPath PRECISION Registry

Additional relevant MeSH terms:
Cardiovascular Diseases
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Vascular Diseases
Arterial Occlusive Diseases
Pathologic Processes processed this record on April 24, 2017